The merger is a reverse shell transaction where Remix is effectively acquiring Passage Bio's public listing. Existing PASG holders face extreme dilution (~6% pro forma). The CVRs are speculative and likely worthless. The combined company's value depends entirely on Remix's clinical execution for REM-422. Monitor the special meeting vote on Nov 5, 2026, and subsequent clinical data for REM-422.
Price Chart
Executive Summary
Passage Bio (PASG) filed Amendment No. 4 to its S-4 registration statement for the proposed reverse merger with Remix Therapeutics. Under the merger agreement, Remix equityholders (excluding PIPE investors) will own ~65% of the combined company, existing Passage Bio stockholders ~6%, and Concurrent Financing investors ~29%, based on a Remix valuation of $226M and anticipated Passage Bio net cash of ~$10.9M at closing. The combined company will be renamed Remix Therapeutics, Inc. and trade under the symbol RMTX, with Remix management and board in control — a de facto acquisition of Passage Bio's public listing by Remix.
Key Facts
- Existing Passage Bio stockholders expected to own only ~6% of the combined company post-merger, representing massive dilution.
- Remix valued at $226M; Passage Bio valued at ~$20M (subject to net cash adjustment).
- Concurrent Financing of ~$100M ($70M subscription + $30M convertible notes) expected to close with the merger.
- Passage Bio stockholders will receive one CVR per share for potential contingent payments from Gemma Biotherapeutics license proceeds (GM1 program by July 2028; MLD program by Dec 2027).
- Passage Bio has wound down its gene therapy programs and reduced workforce by ~75%.
- Passage Bio incurred net losses of $45.5M (2025) and $64.8M (2024), with an accumulated deficit of $720.1M as of June 30, 2026.
- Passage Bio had only 3,217,810 shares outstanding as of the record date; stock closed at $4.12 on Oct 2, 2026.
- Remix's lead candidate REM-422 is in Phase 1/2 for AML, HR-MDS, and ACC; FDA granted Fast Track designation for ACC.
- Remix has a collaboration with Roche; has never generated product revenue; has a going-concern risk per its auditor.
- Passage Bio's financial advisor (Redwood) opined the merger consideration is fair to Passage Bio.
- Termination fees: Passage Bio pays $1.5M; Remix pays up to $17.5M.
- Lock-up agreements lock up ~99% of Remix shares for 180 days post-closing.
- Combined company expected to trade on Nasdaq under symbol RMTX.
Financial Impact
Existing Passage Bio stockholders diluted from 100% to ~6% ownership. Remix stockholders get ~65%, PIPE investors ~29%. Combined company implied value ~$346M.
Risk Factors
- Massive dilution for existing PASG stockholders (~94% ownership loss).
- CVRs may expire worthless if Gemma payments are not received.
- Remix has only one clinical-stage candidate (REM-422) with high development risk.
- Remix has a going-concern risk and no product revenue.
- Integration risk and potential Nasdaq delisting if listing conditions are not met.
- Litigation risk from stockholder lawsuits challenging the merger.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001140361-26-039151 |
| Document: ny20077915x12_ex23-1.htm | 0001140361-26-039151 |
| Document: ny20077915x12_ex23-2.htm | 0001140361-26-039151 |
| Document: 0001140361-26-039151-index-headers.html | 0001140361-26-039151 |
| Document: 0001140361-26-039151-index.html | 0001140361-26-039151 |
| Document: 0001140361-26-039151.txt | 0001140361-26-039151 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | EFFECT | $3.64 | awaiting T+20 | — | $3.36 (−7.72%) |
Oct 8, 2026 18d ago | S-4/A | $3.69 | awaiting T+20 | — | $3.36 (+8.97%) |
Oct 5, 2026 21d ago | S-4/A | $4.08 | awaiting T+20 | — | $3.36 (−17.67%) |
Sep 21, 2026 5w ago | S-4/A | $4.95 $3.60 | ▼ −27.27% | ▼ −26.71% | $3.36 (−32.14%) |
Sep 2, 2026 7w ago | S-4/A / 425 | $4.75 $4.12 | ▲ +13.26% | ▲ +12.08% | $3.36 (+29.28%) |
Sep 2, 2026 7w ago | 8-K | $4.75 $4.12 | ▼ −13.26% | ▼ −12.08% | $3.36 (−29.28%) |
Jun 24, 2026 17w ago | 425 | $4.33 $4.90 | ▼ −13.16% | ▼ −12.64% | $3.36 (+22.42%) |
Jun 24, 2026 17w ago | 425 | $4.33 $4.90 | ▼ −13.16% | ▼ −12.64% | $3.36 (+22.42%) |
Jun 24, 2026 17w ago | 8-K | $4.33 $4.90 | ▼ −13.16% | ▼ −12.64% | $3.36 (+22.42%) |
May 27, 2026 21w ago | 8-K | $5.71 $4.70 | ▲ +17.69% | ▲ +14.54% | $3.36 (+41.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers